A Look Back At 2010: In Search Of New Biopharma Models

2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.

The dealmaking trends of 2010 solidified patterns that first surfaced in 2009 (minus the megamergers): risk-sharing deal structures, an emphasis on diversification and emerging markets, and earlier access to new products and technologies. CVRs became a household acronym and – as Sanofi' continued attempts to buy Genzyme Corp. clearly demonstrate – have moved well beyond acquisitions of private biotechs. Options were once again de rigueur. [See Deal] Aside from the increased familiarity with an important deal structure was greater awareness of reimbursement issues and a renewed emphasis on the kinds of innovation that can find lower tier formulary placement. Perhaps as a direct extension of that awareness, companies continued to emphasize their ambitions to focus on unmet medical need – in some cases drawing industry's largest companies to build up presence in niche or rare diseases that had previously been attractive markets only to small biotechs.

More from Business Strategy

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By 

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

Licensing For Innovation: A Decade Of Pharma Product Deals

 

Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.

More from In Vivo

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By 

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Podcast: Heranova CMO Advocates For Endometriosis Awareness: “Pain Is Not Normal”

 

Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.